Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BCMA/GPRC5D CAR-T in Relapsed/Refractory Multiple Myeloma
NCT07196124Phase 1Withdrawn
- Sponsor
- Guangzhou Bio-gene Technology Co., Ltd.
- Start
- Oct 2025
- Primary completion
- Oct 2028
- Modality
- CAR-T Cells
01
Overview
Phase 1, open-label, single-arm trial of BCMA/GPRC5D CAR-T in multiple myeloma (MM), sponsored by Guangzhou Bio-gene Technology Co., Ltd. Primary endpoints: Dose Limited Toxicity Rate at 28 days and Incidence of Treatment-Emergent Adverse Events at 24 months. Planned start Oct 2025; status: withdrawn.
02
Drugs
BCMA/GPRC5D CAR-T
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT07196124.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07196124.